

Mode of Action 1 (MoA 1)

- PD-1 mediated T cell inhibition
- Suppression of all PD-1+ T cells

CD1a-autoreactive T cells

- Implicated in AD disease pathology

Mode of Action 2 (MoA 2)

- CD1a-blockade
- Inhibition of CD1a autoreactive T cells





FIG. 1A

2/38

Healthy donor skin



AD lesional skin




FIG. 1B




FIG. 2




FIG. 3

5/38




FIG. 4




FIG. 5A




FIG. 5B




FIG. 5D




FIG. 5C




FIG. 6




FIG. 7A




FIG. 7B




FIG. 7C




FIG. 7D




FIG. 8




FIG. 9A

15/38




FIG. 9B




FIG. 9C




FIG. 9D

18/38




FIG. 10A




FIG. 10B

20/38




FIG. 11A




FIG. 11B




FIG. 11C




FIG. 12A

Antibody	Most human variant	Human % (FW)	# FW mismatches	WT (llama) Tm (°C)	Humanised Tm (°C)	WT (llama) KD 37°C (pM)	Humanised KD 37°C (pM)
AB002	V10	89%	9	60	61.3	288	448
AB007	V11	89%	9	60.1	61.1	1700	2600
AB052	V9	90%	8	60.5	60.8	840	3500

FIG. 12B




FIG. 13A




FIG. 13B




FIG. 13D




FIG. 13C




FIG. 13F




FIG. 13E




FIG. 13G




FIG. 131




FIG. 13H




FIG. 13J




FIG. 14A




FIG. 14B

31/38




FIG. 15A

D0 to D4




FIG. 15B




FIG. 15C




FIG. 16A




FIG. 16B

FIG. 16C




FIG. 16D




FIG. 17




FIG. 18




FIG. 19




FIG. 20A



FIG. 20B




FIG. 20C